This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NameElagolix
Accession NumberDB11979  (DB05694)
TypeSmall Molecule
GroupsInvestigational
Description

Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding.

Structure
Thumb
SynonymsNot Available
External IDs NBI-56418
Product Ingredients
IngredientUNIICASInChI KeyDetails
Elagolix Sodium5948VUI423 832720-36-2DQYGXRQUFSRDCH-UQIIZPHYSA-MDetails
ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
CategoriesNot Available
UNII5B2546MB5Z
CAS number834153-87-6
WeightAverage: 631.6
Monoisotopic: 631.210561893
Chemical FormulaC32H30F5N3O5
InChI KeyHEAUOKZIVMZVQL-VWLOTQADSA-N
InChI
InChI=1S/C32H30F5N3O5/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42)/t25-/m0/s1
IUPAC Name
4-{[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-4-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-1-yl]-1-phenylethyl]amino}butanoic acid
SMILES
COC1=C(F)C(=CC=C1)C1=C(C)N(CC2=C(C=CC=C2F)C(F)(F)F)C(=O)N(C[[email protected]](NCCCC(O)=O)C2=CC=CC=C2)C1=O
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action

Elagolix is a specific highly potent non-peptide, orally active antagonist of the GnRH receptor. This compound inhibits pituitary luteinizing hormone (LH) secretion directly, potentially preventing the several week delay and flare associated with peptide agonist therapy.

TargetKindPharmacological actionActionsOrganismUniProt ID
Gonadotropin-releasing hormone receptorProteinunknownNot AvailableHumanP30968 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions Not Available
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceFolliculogenesis1
2CompletedTreatmentEndometriosis3
2CompletedTreatmentEndometriosis, Pain1
2CompletedTreatmentEndometriosis / Pain1
2CompletedTreatmentHeavy Uterine Bleeding / Uterine Leiomyomas1
3Active Not RecruitingTreatmentEndometriosis1
3Active Not RecruitingTreatmentHeavy Menstrual Bleeding / Uterine Leiomyomas2
3CompletedTreatmentEndometriosis3
3Enrolling by InvitationTreatmentHeavy Menstrual Bleeding / Uterine Leiomyomas1
Properties
StateNot Available
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00243 mg/mLALOGPS
logP4.68ALOGPS
logP3.14ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)3.86ChemAxon
pKa (Strongest Basic)9.04ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.18 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity156.06 m3·mol-1ChemAxon
Polarizability59.57 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as gamma amino acids and derivatives. These are amino acids having a (-NH2) group attached to the gamma carbon atom.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentGamma amino acids and derivatives
Alternative ParentsTrifluoromethylbenzenes / Anisoles / Methoxybenzenes / Phenoxy compounds / Aralkylamines / Alkyl aryl ethers / Amino fatty acids / Fluorobenzenes / Pyrimidones / Hydropyrimidines
SubstituentsGamma amino acid or derivatives / Trifluoromethylbenzene / Phenoxy compound / Anisole / Phenol ether / Methoxybenzene / Alkyl aryl ether / Amino fatty acid / Halobenzene / Pyrimidone
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Peptide binding
Specific Function:
Receptor for gonadotropin releasing hormone (GnRH) that mediates the action of GnRH to stimulate the secretion of the gonadotropic hormones luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This receptor mediates its action by association with G-proteins that activate a phosphatidylinositol-calcium second messenger system. Isoform 2 may act as an inhibitor of GnRH-R signaling.
Gene Name:
GNRHR
Uniprot ID:
P30968
Uniprot Name:
Gonadotropin-releasing hormone receptor
Molecular Weight:
37730.355 Da
Drug created on October 20, 2016 15:07 / Updated on June 11, 2017 21:30